Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term Study of TAU-284 in Paediatric Patients With Perennial Allergic Rhinitis

Trial Profile

A Long-Term Study of TAU-284 in Paediatric Patients With Perennial Allergic Rhinitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bepotastine (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Registrational
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 26 May 2015 Mitsubishi Tanabe received approval for bepotastine [Talion and Talion OD tablets] for additional pediatric allergic diseases (for children at least seven years of age) in Japan. This approval was based on efficacy and safety results from trials conducted in pediatric patients in Japan.
    • 15 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top